{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:48:35Z","timestamp":1790938115404,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.clml.2023.05.002","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T02:15:26Z","timestamp":1684203326000},"page":"674-686","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Phase 1\/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies"],"prefix":"10.1016","volume":"23","author":[{"given":"Manish R.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Donnellan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Asch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria R.","family":"Baer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir T.","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9040-7415","authenticated-orcid":false,"given":"Andrew T.","family":"Kuykendall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Marando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Savona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.05.002_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107454","article-title":"Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer","volume":"207","author":"Malone","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clml.2023.05.002_bib0002","doi-asserted-by":"crossref","first-page":"109","DOI":"10.15430\/JCP.2018.23.3.109","article-title":"PIM kinase as an executional target in cancer","volume":"23","author":"Zhang","year":"2018","journal-title":"J Cancer Prev"},{"key":"10.1016\/j.clml.2023.05.002_bib0003","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-014-0095-z","article-title":"Pim kinases in hematological malignancies: where are we now and where are we going?","volume":"7","author":"Mondello","year":"2014","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2023.05.002_bib0004","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrc2986","article-title":"For better or for worse: the role of Pim oncogenes in tumorigenesis","volume":"11","author":"Nawijn","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2023.05.002_bib0005","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood-2013-01-481457","article-title":"Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation","volume":"122","author":"Lu","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.05.002_bib0006","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1080\/10428190310001641251","article-title":"Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma","volume":"45","author":"Cohen","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.05.002_bib0007","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/35085588","article-title":"Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas","volume":"412","author":"Pasqualucci","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.clml.2023.05.002_bib0008","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1182\/blood-2007-07-102186","article-title":"The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes","volume":"111","author":"Wernig","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.05.002_bib0009","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3324\/haematol.2009.017079","article-title":"PIM serine\/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers","volume":"95","author":"Brault","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2023.05.002_bib0010","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood-2004-05-2006","article-title":"Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival","volume":"105","author":"Kim","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.05.002_bib0011","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1038\/bcj.2015.46","article-title":"Targeting the Pim kinases in multiple myeloma","volume":"5","author":"Keane","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2023.05.002_bib0012","doi-asserted-by":"crossref","first-page":"9151","DOI":"10.1007\/s13277-016-4806-7","article-title":"Expression of Pim-3 in colorectal cancer and its relationship with prognosis","volume":"37","author":"Zhou","year":"2016","journal-title":"Tumour Biol"},{"key":"10.1016\/j.clml.2023.05.002_bib0013","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13046-016-0406-z","article-title":"PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value","volume":"35","author":"Xu","year":"2016","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.clml.2023.05.002_bib0014","first-page":"4451","article-title":"Prognostic impact of protein overexpression of the proto-oncogene PIM-1 in gastric cancer","volume":"29","author":"Warnecke-Eberz","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clml.2023.05.002_bib0015","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.12659\/MSM.898223","article-title":"Pim-3 is a critical risk factor in development and prognosis of prostate cancer","volume":"22","author":"Qu","year":"2016","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.clml.2023.05.002_bib0016","doi-asserted-by":"crossref","first-page":"e76693","DOI":"10.1371\/journal.pone.0076693","article-title":"Expression of pim-1 in tumors, tumor stroma and tumor-adjacent mucosa co-determines the prognosis of colon cancer patients","volume":"8","author":"Peng","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2023.05.002_bib0017","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1593\/neo.81038","article-title":"Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor","volume":"11","author":"Peltola","year":"2009","journal-title":"Neoplasia"},{"key":"10.1016\/j.clml.2023.05.002_bib0018","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/jso.21627","article-title":"Overexpression of Pim-1 is associated with poor prognosis in patients with esophageal squamous cell carcinoma","volume":"102","author":"Liu","year":"2010","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.clml.2023.05.002_bib0019","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1080\/10428190802419640","article-title":"Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study","volume":"49","author":"Hsi","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.05.002_bib0020","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1182\/blood-2011-03-344374","article-title":"PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma","volume":"118","author":"G\u00f3mez-Abad","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.05.002_bib0021","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1021\/pr500651n","article-title":"PIM2 kinase is induced by cisplatin in ovarian cancer cells and limits drug efficacy","volume":"13","author":"Musiani","year":"2014","journal-title":"J Proteome Res"},{"key":"10.1016\/j.clml.2023.05.002_bib0022","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1365-2141.2011.08792.x","article-title":"Targeting PIM kinase activity significantly augments the efficacy of cytarabine","volume":"156","author":"Kelly","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.05.002_bib0023","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.drup.2011.04.002","article-title":"The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms","volume":"14","author":"Isaac","year":"2011","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.clml.2023.05.002_bib0024","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1084\/jem.20110846","article-title":"Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma","volume":"208","author":"Schatz","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.clml.2023.05.002_bib0025","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.leukres.2011.07.011","article-title":"A potential therapeutic target for FLT3-ITD AML: PIM1 kinase","volume":"36","author":"Fathi","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2023.05.002_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199108","article-title":"Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies","volume":"13","author":"Koblish","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2023.05.002_bib0027","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1182\/bloodadvances.2019000260","article-title":"The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN","volume":"3","author":"Mazzacurati","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.05.002_bib0028","unstructured":"SuperGen, Inc. discontinues clinical development of SGI-1776, a phase I PIM inhibitor [press release]. https:\/\/www.biospace.com\/article\/releases\/supergen-inc-discontinues-clinical-development-of-sgi-1776-a-phase-i-pim-inhibitor-\/. Published November 11, 2010. Accessed December 3, 2020."},{"key":"10.1016\/j.clml.2023.05.002_bib0029","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1038\/s41375-019-0482-0","article-title":"The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and\/or refractory multiple myeloma","volume":"33","author":"Raab","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.05.002_bib0030","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41416-018-0082-1","article-title":"Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers","volume":"118","author":"Cortes","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2023.05.002_bib0031","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.1128\/MCB.24.13.6104-6115.2004","article-title":"Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors","volume":"24","author":"Mikkers","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.clml.2023.05.002_bib0032","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1756-8722-6-12","article-title":"Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice","volume":"6","author":"An","year":"2013","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2023.05.002_bib0033","unstructured":"VIDAZA\u00ae (azacitidine) [prescribing information] Summit, NJ: Celgene Corporation; 2020."},{"key":"10.1016\/j.clml.2023.05.002_bib0034","unstructured":"CYTARABINE (cytarabine) [package insert]. Lake Forest, IL: Hospira, Inc; 2020."},{"key":"10.1016\/j.clml.2023.05.002_bib0035","unstructured":"JAKAFI\u00ae (ruxolitinib) [package insert]. Wilmington, DE: Incyte Corporation; 2019."},{"key":"10.1016\/j.clml.2023.05.002_bib0036","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1200\/JCO.2020.38.15_suppl.3586","article-title":"A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654 administered daily for 28 days to patients with advanced solid tumors","volume":"38","author":"Garrido-Laguna","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2023.05.002_bib0037","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1158\/1078-0432.CCR-17-1629","article-title":"Concurrent inhibition of Pim and FLT3 kinases enhances apoptosis of FLT3-ITD acute myeloid leukemia cells through increased Mcl-1 proteasomal degradation","volume":"24","author":"Kapoor","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2023.05.002_bib0038","doi-asserted-by":"crossref","first-page":"8870","DOI":"10.18632\/oncotarget.22926","article-title":"FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K\/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1\/Mcl-1 pathway","volume":"9","author":"Okada","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2023.05.002_bib0039","article-title":"A new compound with increased antitumor activity by cotargeting MEK and Pim-1","volume":"23","author":"Li","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.clml.2023.05.002_bib0040","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3109\/10428194.2015.1063141","article-title":"Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells","volume":"57","author":"Cervantes-Gomez","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.05.002_bib0041","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1158\/0008-5472.CAN-11-3240","article-title":"Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737","volume":"72","author":"Song","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2023.05.002_bib0042","unstructured":"VENCLEXTA\u00ae (venetoclax tablets) [prescribing information]. North Chicago, IL: AbbVie Inc.; 2020."},{"key":"10.1016\/j.clml.2023.05.002_bib0043","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/10428194.2020.1719098","article-title":"Venetoclax in acute myeloid leukemia - current and future directions","volume":"61","author":"Lachowiez","year":"2020","journal-title":"Leuk Lymphoma"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:42:16Z","timestamp":1761871336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023001428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2152265023001428"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.05.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1\/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Incyte Corporation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}